Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2008 1
2009 1
2010 1
2011 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Huntington's disease and minocycline.
Hödl AK, Bonelli RM. Hödl AK, et al. Mov Disord. 2005 Apr;20(4):510-511. doi: 10.1002/mds.20441. Mov Disord. 2005. PMID: 15806589 No abstract available.
Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY.
Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB; Investigators of the European Huntington's Disease Network. Orth M, et al. PLoS Curr. 2010 Sep 28;2:RRN1184. doi: 10.1371/currents.RRN1184. PLoS Curr. 2010. PMID: 20890398 Free PMC article.
BACKGROUND: Huntington's disease (HD) is a rare triplet repeat (CAG) disorder. Advanced, multi-centre, multi-national research frameworks are needed to study simultaneously multiple complementary aspects of HD. ...METHODS: We report on cross-sectional data of the first 176 …
BACKGROUND: Huntington's disease (HD) is a rare triplet repeat (CAG) disorder. Advanced, multi-centre, multi-national research framew …
NMDA receptor gene variations as modifiers in Huntington disease: a replication study.
Saft C, Epplen JT, Wieczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG, Dose M, Tabrizi SJ, Craufurd D; REGISTRY Investigators of the European Huntington's Disease Network; Arning L. Saft C, et al. PLoS Curr. 2011 Oct 4;3:RRN1247. doi: 10.1371/currents.RRN1247. PLoS Curr. 2011. PMID: 21989477 Free PMC article.
Several candidate modifier genes which, in addition to the pathogenic CAG repeat expansion, influence the age at onset (AO) in Huntington disease (HD) have already been described. The aim of this study was to replicate association of variations in the N-methyl D-aspartate …
Several candidate modifier genes which, in addition to the pathogenic CAG repeat expansion, influence the age at onset (AO) in Huntington …
Ideomotor limb apraxia in Huntington's disease: a case-control study.
Hödl AK, Hödl E, Otti DV, Herranhof B, Ille R, Bonelli RM. Hödl AK, et al. J Neurol. 2008 Mar;255(3):331-9. doi: 10.1007/s00415-008-0577-4. Epub 2008 Mar 4. J Neurol. 2008. PMID: 18305889
However, this symptom may also occur in dementia with subcortical lesions like Huntington's disease (HD), a hereditary, devastating neurodegenerative disease leading to neurological and psychiatric dysfunction. ...
However, this symptom may also occur in dementia with subcortical lesions like Huntington's disease (HD), a hereditary, devastating n …
Impaired ideomotor limb apraxia in cortical and subcortical dementia: a comparison of Alzheimer's and Huntington's disease.
Holl AK, Ille R, Wilkinson L, Otti DV, Hödl E, Herranhof B, Reisinger KM, Müller N, Painold A, Holl EM, Letmaier M, Bonelli RM. Holl AK, et al. Neurodegener Dis. 2011;8(4):208-15. doi: 10.1159/000322230. Epub 2011 Jan 5. Neurodegener Dis. 2011. PMID: 21212634
BACKGROUND: Although ideomotor limb apraxia is often considered to occur only in dementia with cortical involvement like Alzheimer's disease (AD), it is also frequently seen in dementia with subcortical degeneration like Huntington's disease (HD). METHODS: To assess the oc …
BACKGROUND: Although ideomotor limb apraxia is often considered to occur only in dementia with cortical involvement like Alzheimer's disease …
Neuroprotection in Huntington's disease: a 2-year study on minocycline.
Bonelli RM, Hödl AK, Hofmann P, Kapfhammer HP. Bonelli RM, et al. Int Clin Psychopharmacol. 2004 Nov;19(6):337-42. doi: 10.1097/00004850-200411000-00004. Int Clin Psychopharmacol. 2004. PMID: 15486519 Clinical Trial.
Huntington's disease (HD), a relentlessly progressive neurodegenerative disorder, is characterized by a clinical triad of psychiatric, cognitive and motor disturbances. ...
Huntington's disease (HD), a relentlessly progressive neurodegenerative disorder, is characterized by a clinical triad of psychiatric …
Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease.
Aziz NA, Jurgens CK, Landwehrmeyer GB; EHDN Registry Study Group; van Roon-Mom WM, van Ommen GJ, Stijnen T, Roos RA. Aziz NA, et al. Neurology. 2009 Oct 20;73(16):1280-5. doi: 10.1212/WNL.0b013e3181bd1121. Epub 2009 Sep 23. Neurology. 2009. PMID: 19776381
OBJECTIVE: Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in the HD gene (HTT). ...CONCLUSIONS: Increasing CAG repeat size in normal HTT diminishes the association between mutant CAG repeat size and disease seve …
OBJECTIVE: Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in the HD gen …